JPH07503481A - オピオイド鎮痛剤の極性代謝物を含有する鼻腔投与用組成物 - Google Patents
オピオイド鎮痛剤の極性代謝物を含有する鼻腔投与用組成物Info
- Publication number
- JPH07503481A JPH07503481A JP5513869A JP51386993A JPH07503481A JP H07503481 A JPH07503481 A JP H07503481A JP 5513869 A JP5513869 A JP 5513869A JP 51386993 A JP51386993 A JP 51386993A JP H07503481 A JPH07503481 A JP H07503481A
- Authority
- JP
- Japan
- Prior art keywords
- morphine
- glucuronide
- composition
- metabolites
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1、 オピオイド鎮痛剤の極性代出物と吸収促進剤からなる、鼻腔投与用組成物 。 2、前記代謝物がグルクロニドである、請求項1に記載の組成物。 3、前記代謝物がサルフェートである、請求項1に記載の緯組物。 4、前記グルクロニドがモルフイン−6−グルクロニドである、請求項2に記載 の組成物。 5、前記サルフェートがモルフィン−6−サルフェートである、請求項3に記載 の組成物。 6、前記吸収促進剤が、カチオン性ポリマー、生物付着性剤、表面活性剤、脂肪 酸、キレート剤、粘液溶解性剤、シクロデキストリン、または小球体調製剤、ま たはそれらの組み合わせである、請求項1ないし5のいずれか一項に記載の組成 物。 7、前記吸収促進剤が、キトサンである、請求項6に記載の組成物。 8、前記組成物が、吸収促進剤の溶液または分散液からなる、請求項1ないし7 のいずれか一項に記載の組成物。 9、前記組成物が、吸収促進剤としての小球体からなる、請求項1ないし7のい ずれか一項に記載の組成物。 10、実施例に実質的に記載されているような組成物。 11、請求項1ないし10のいずれか一項に記載の組成物を、鼻腔粘膜に投与す ることからなる、痛み軽減方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929202464A GB9202464D0 (en) | 1992-02-05 | 1992-02-05 | Composition for nasal administration |
GB9202464.5 | 1992-02-05 | ||
PCT/GB1993/000228 WO1993015737A1 (en) | 1992-02-05 | 1993-02-04 | Compositions for nasal administration containing polar metabolites of opioid analgesics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07503481A true JPH07503481A (ja) | 1995-04-13 |
JP3958352B2 JP3958352B2 (ja) | 2007-08-15 |
Family
ID=10709891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51386993A Expired - Lifetime JP3958352B2 (ja) | 1992-02-05 | 1993-02-04 | オピオイド鎮痛剤の極性代謝物を含有する鼻腔投与用組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5629011A (ja) |
EP (1) | EP0625044B1 (ja) |
JP (1) | JP3958352B2 (ja) |
AT (1) | ATE171872T1 (ja) |
AU (1) | AU665806B2 (ja) |
CA (1) | CA2127805C (ja) |
DE (1) | DE69321458T2 (ja) |
DK (1) | DK0625044T3 (ja) |
ES (1) | ES2123660T3 (ja) |
GB (2) | GB9202464D0 (ja) |
NO (1) | NO306283B1 (ja) |
WO (1) | WO1993015737A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005281315A (ja) * | 1997-07-02 | 2005-10-13 | Aventis Pharmaceuticals Holdings Inc | 水性薬理組成物 |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
JP2012176993A (ja) * | 2000-02-08 | 2012-09-13 | Euro-Celtique Sa | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1247472B (it) * | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
DK0865789T3 (da) * | 1993-03-26 | 2005-07-18 | Franciscus Wilhelmus He Merkus | Farmaceutiske præparater til intranasal administration af dihydroergotamin |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
GB2282758A (en) * | 1993-08-23 | 1995-04-19 | Euro Celtique Sa | Oral morphine-6-glucuronide compositions |
DE4403709A1 (de) * | 1994-02-07 | 1995-08-10 | Lohmann Therapie Syst Lts | Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
US5858408A (en) * | 1994-07-20 | 1999-01-12 | Toyama Chemical Co., Ltd. | Sustained-release oral ointment |
GB9416884D0 (en) * | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US6403602B1 (en) * | 1997-02-20 | 2002-06-11 | The University Of Kentucky Research Foundation | Morphine-6-sulfate analogues and their use for the treatment of pain |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
AU747211B2 (en) * | 1997-07-18 | 2002-05-09 | Bayer Corporation | Methods of removing residual solvent from nasal drug delivery compositions |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
JP4234803B2 (ja) * | 1997-10-27 | 2009-03-04 | 久光製薬株式会社 | 薬物放出速度が制御された医薬組成物 |
FR2771929B1 (fr) * | 1997-12-09 | 2001-02-23 | Biovector Therapeutics | Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
ATE265846T1 (de) * | 1998-02-25 | 2004-05-15 | Abbott Lab | Butorphanol enthaltende formulierungen mit verzögerter freisetzung |
US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
US6608073B1 (en) * | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
FR2787029A1 (fr) * | 1998-12-09 | 2000-06-16 | Biovector Therapeutics | Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central |
US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6451286B1 (en) | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
GB9908921D0 (en) * | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
US6225343B1 (en) | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
NZ515783A (en) | 1999-06-16 | 2004-05-28 | Nastech Pharmaceutical Co | Pharmaceutical formulations and methods comprising intranasal morphine |
AU5169200A (en) * | 1999-06-16 | 2001-01-02 | Nastech Pharmaceutical Co., Inc. | Methods and compositions for treating breakthrough pain |
GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
US6863896B1 (en) | 1999-10-26 | 2005-03-08 | Chiron Corporation | Plant lectins as mucosal adjuvants |
EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP1255547B1 (en) * | 2000-02-08 | 2008-08-20 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
FR2811227A1 (fr) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
US8257744B2 (en) | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
EP1315533A4 (en) * | 2000-08-15 | 2007-06-27 | Univ Kentucky Res Found | PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION |
KR101167465B1 (ko) | 2000-10-30 | 2012-07-27 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
US20030044356A1 (en) * | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
WO2003004031A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
DE60223037T2 (de) | 2001-08-16 | 2008-07-24 | Cmp Therapeutics Ltd. | Chitin-mikropartikel und ihre medizinische verwendung |
AU2002337686B2 (en) * | 2001-09-26 | 2008-05-15 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
WO2003066068A1 (en) * | 2002-02-01 | 2003-08-14 | Intradigm Corporation | Hpma-polyamine conjugates and uses therefore |
WO2004003145A2 (en) * | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
JP2006021996A (ja) * | 2002-07-04 | 2006-01-26 | Dainippon Sumitomo Pharma Co Ltd | 置換ヒドロキシピリジン化合物の抱合体 |
CN1703200B (zh) * | 2002-09-20 | 2012-02-29 | 奥尔制药公司 | 隔离亚单元和相关组合物及方法 |
DE10248601B4 (de) * | 2002-10-17 | 2006-05-24 | Goldstein, Naum, Dr.habil.nat. | Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems |
US7445769B2 (en) * | 2002-10-31 | 2008-11-04 | Cadbury Adams Usa Llc | Compositions for removing stains from dental surfaces and methods of making and using the same |
GB0302738D0 (en) * | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Composition |
CN100575955C (zh) * | 2003-04-30 | 2009-12-30 | 纳斯泰克制药公司 | 密蛋白的未表达作为肿瘤转移的标记物 |
EP1622448A2 (en) * | 2003-05-01 | 2006-02-08 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Nasal administration of the lh-rh analog leuprolide |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
US20050129679A1 (en) * | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
US20050175679A1 (en) * | 2004-02-10 | 2005-08-11 | Michael Moshman | Controlled release formulations |
GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20050283004A1 (en) * | 2004-06-18 | 2005-12-22 | Hopax Chemicals Manufacturing Co., Ltd. | Alkylsulfonated polyaminosaccharides |
GB0416328D0 (en) * | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
US7641892B2 (en) * | 2004-07-29 | 2010-01-05 | Cadburry Adams USA, LLC | Tooth whitening compositions and delivery systems therefor |
US7115561B2 (en) * | 2004-09-22 | 2006-10-03 | Patterson James A | Medicament composition and method of administration |
CA2601773A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
JP2009506076A (ja) | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
AU2007285472B2 (en) * | 2006-03-30 | 2013-10-24 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
DK2719378T3 (en) | 2006-06-19 | 2016-10-17 | Alpharma Pharmaceuticals Llc | pharmaceutical compositions |
WO2008011596A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
EP2073797A2 (en) * | 2006-10-11 | 2009-07-01 | Alpharma, Inc. | Pharmaceutical compositions |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
EP2112923A1 (en) | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
DK2706982T4 (da) | 2011-05-13 | 2021-05-10 | Euro Celtique Sa | Intranasale farmaceutiske dosisformer omfattende naloxon |
US11413239B2 (en) | 2011-07-20 | 2022-08-16 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol for nasal administration |
CA2942078C (en) | 2014-03-14 | 2023-03-14 | The University Of North Carolina At Chapel Hill | Small molecules for inhibiting male fertility |
EP4331670A2 (en) | 2015-01-07 | 2024-03-06 | Tonix Pharma Limited | Magnesium-containing oxytocin formulations and methods of use |
FR3032353B1 (fr) | 2015-02-06 | 2017-03-10 | Jacques Seguin | Composition pharmaceutique et dispositif pour le traitement de la douleur |
AU2017345765A1 (en) * | 2016-10-21 | 2019-06-06 | Somniferum Labs LLC | Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction |
EP3568126B1 (en) | 2017-01-11 | 2023-11-01 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
US10292948B2 (en) | 2017-01-11 | 2019-05-21 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
US10639294B2 (en) | 2018-10-02 | 2020-05-05 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite |
US11304968B2 (en) | 2018-11-16 | 2022-04-19 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide |
CN110257025B (zh) * | 2019-07-03 | 2020-07-03 | 中国石油大学(华东) | 水基钻井液用环糊精微球超高温降滤失剂及其制备方法以及水基钻井液和应用 |
US20230372327A1 (en) * | 2020-10-15 | 2023-11-23 | Pharmbiotest Poland Sp. z o. o. | Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
DE3602370A1 (de) * | 1986-01-27 | 1987-08-06 | Chrubasik Sigrun | Verwendung von analgetica durch inhalation |
GB8918879D0 (en) * | 1989-08-18 | 1989-09-27 | Danbiosyst Uk | Pharmaceutical compositions |
US5240932A (en) * | 1990-03-30 | 1993-08-31 | Yasunori Morimoto | Percutaneously absorbable compositions of morphine or analogous analgesics of morphine |
FR2665357B1 (fr) * | 1990-07-31 | 1995-03-31 | Aiache Jean Marc | Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee. |
JPH07505655A (ja) * | 1992-04-13 | 1995-06-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | アルコール乱用の処置のためのデルタオピオイドレセプター選択的ベンジリデン置換化モルヒナン |
-
1992
- 1992-02-05 GB GB929202464A patent/GB9202464D0/en active Pending
-
1993
- 1993-02-04 DE DE69321458T patent/DE69321458T2/de not_active Expired - Lifetime
- 1993-02-04 JP JP51386993A patent/JP3958352B2/ja not_active Expired - Lifetime
- 1993-02-04 EP EP93917408A patent/EP0625044B1/en not_active Expired - Lifetime
- 1993-02-04 CA CA002127805A patent/CA2127805C/en not_active Expired - Lifetime
- 1993-02-04 AT AT93917408T patent/ATE171872T1/de active
- 1993-02-04 WO PCT/GB1993/000228 patent/WO1993015737A1/en active IP Right Grant
- 1993-02-04 ES ES93917408T patent/ES2123660T3/es not_active Expired - Lifetime
- 1993-02-04 US US08/256,431 patent/US5629011A/en not_active Expired - Lifetime
- 1993-02-04 DK DK93917408T patent/DK0625044T3/da active
- 1993-02-04 GB GB9413102A patent/GB2277682B/en not_active Revoked
- 1993-02-04 AU AU34580/93A patent/AU665806B2/en not_active Expired
-
1994
- 1994-07-27 NO NO942787A patent/NO306283B1/no not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005281315A (ja) * | 1997-07-02 | 2005-10-13 | Aventis Pharmaceuticals Holdings Inc | 水性薬理組成物 |
JP2012176993A (ja) * | 2000-02-08 | 2012-09-13 | Euro-Celtique Sa | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
JP2014169306A (ja) * | 2000-02-08 | 2014-09-18 | Euro-Celtique Sa | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
JP2010174029A (ja) * | 2002-03-19 | 2010-08-12 | Archimedes Development Ltd | 鎮痛薬 |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
NO942787L (no) | 1994-07-27 |
US5629011A (en) | 1997-05-13 |
AU3458093A (en) | 1993-09-03 |
DE69321458D1 (de) | 1998-11-12 |
CA2127805C (en) | 2004-03-30 |
EP0625044B1 (en) | 1998-10-07 |
NO306283B1 (no) | 1999-10-18 |
JP3958352B2 (ja) | 2007-08-15 |
NO942787D0 (no) | 1994-07-27 |
GB9413102D0 (en) | 1994-08-31 |
GB2277682A (en) | 1994-11-09 |
GB9202464D0 (en) | 1992-03-18 |
GB2277682B (en) | 1995-12-20 |
ATE171872T1 (de) | 1998-10-15 |
DK0625044T3 (da) | 1999-06-21 |
EP0625044A1 (en) | 1994-11-23 |
WO1993015737A1 (en) | 1993-08-19 |
DE69321458T2 (de) | 1999-03-18 |
AU665806B2 (en) | 1996-01-18 |
CA2127805A1 (en) | 1993-08-19 |
ES2123660T3 (es) | 1999-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07503481A (ja) | オピオイド鎮痛剤の極性代謝物を含有する鼻腔投与用組成物 | |
JP4728580B2 (ja) | 製剤 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
JP4754067B2 (ja) | 鼻孔投与用組成物 | |
US5935604A (en) | Nasal drug delivery composition containing nicotine | |
JP3529142B2 (ja) | シクロデキストリンを含むガレヌス製剤 | |
NO178564B (no) | Framgangsmåte for framstilling av et system for administrering av aktive medikamenter gjennom slimhinner | |
FR2754453A1 (fr) | Preparations pharmaceutiques a administrer par voie nasale | |
JP2002537343A (ja) | 多重粒子製剤 | |
WO1999033491A1 (fr) | Compositions medicinales a liberation prolongee | |
JPH04503508A (ja) | 薬物送達組成物 | |
EP1722759A2 (en) | Chitosan containing solution | |
JP2002528518A (ja) | 粘液付着性ポリマー、その使用およびその製造法 | |
JP2006199589A (ja) | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 | |
JP2003512330A (ja) | シクレソニド含有水性医薬組成物 | |
JP2001510811A (ja) | 生物活性物質を標的に供給するための重合体ベースの薬剤組成物 | |
JP3041627B2 (ja) | アントラサイクリン系抗生物質の安定組成物 | |
WO2003037299A1 (en) | Novel formulation | |
Badadare et al. | Overview on intranasal mucoadhesive drug delivery | |
Dhapte-Pawar et al. | Engineering of Hydrogels for Pulmonary Drug Delivery: Opportunities and Challenges | |
Oberholzer | Peroral and nasal delivery of insulin with PheroidTM technology | |
ZA200407540B (en) | Formulation comprising buprenorphine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040907 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040930 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20041021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060529 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070510 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110518 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120518 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130518 Year of fee payment: 6 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130518 Year of fee payment: 6 |